Source - LSE Regulatory
RNS Number : 5200I
Nuformix PLC
05 December 2022

5 December 2022


Nuformix plc


("Nuformix" or the "Company")


Resignation of Auditor


Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces the resignation of Jeffreys Henry LLP ("Jeffreys Henry") as auditors to the Company.  Section 519 of the Companies Act 2006 (the "Act") requires Jeffreys Henry to send a statement of the reasons for ceasing to hold office.  They have stated that in accordance with Section 519 of the Act, they are ceasing to hold office due to the following reason:


"Jeffreys Henry LLP have resigned as auditor on the grounds that the firm has taken the decision not to register as an auditor eligible to undertake Public Interest Entity audits."


There are no circumstances connected with Jeffreys Henry ceasing to hold office as auditor which they consider should be brought to the attention of the Company's members or creditors.  As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.


The appointment of a new auditor will be announced in due course following the completion of a tender process.




Nuformix plc


Dr Julian Gilbert, Non-executive Chairman


Via IFC Advisory


Stanford Capital Partners Limited


Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes (Corporate Broking)

+44 (0) 20 3650 3652


IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630


About Nuformix


Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Nuformix PLC (NFX)

0p (0.00%)
delayed 16:30PM